CDK9-IN-7

• CAT Number: I018694
• CAS Number: 2369981-71-3
• Molecular Formula: C₂₉H₃₇N₇O₂S
• Molecular Weight: 547.71
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: 7-cyclopentyl-2-[4-(8-isothiocyanatooctanoylamino)anilino]-N,N-dimethylpyrrolo[2,3-d]pyrimidine-6-carboxamide
• InChI: InChI=1S/C29H37N7O2S/c1-35(2)28(38)25-18-21-19-31-29(34-27(21)36(25)24-10-7-8-11-24)33-23-15-13-22(14-16-23)32-26(37)12-6-4-3-5-9-17-30-20-39/h13-16,18-19,24H,3-12,17H2,1-2H3,(H,32,37)(H,31,33,34)
• InChIKey: LLMKBTGLZJIAMY-UHFFFAOYSA-N
• SMILES: CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)NC(=O)CCCCCCCN=C=S

CDK9-IN-7（Cat No.:I018694）is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), an enzyme crucial for regulating transcription and cell cycle progression. By inhibiting CDK9, this compound disrupts the transcriptional machinery that cancer cells rely on for proliferation and survival. Preclinical studies indicate that CDK9-IN-7 effectively induces apoptosis in various cancer cell lines and may enhance the efficacy of other therapies, particularly in cancers characterized by high CDK9 activity. Ongoing research aims to further elucidate its mechanisms of action and evaluate its potential as a therapeutic agent in oncology, targeting transcriptional dysregulation in tumors.

Reference

[1]. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.